Safety and Efficacy of Bone Marrow–Derived Mesenchymal Stem Cells for Chronic Patellar Tendinopathy (With Gap >3 mm) in Patients: 12-Month Follow-up Results of a Phase 1/2 Clinical Trial

BACKGROUND: In a previous study, the authors found that at 6 months after treatment with a 20 × 10(6) dose of bone marrow–derived mesenchymal stem cells (BM-MSCs), patients showed improved tendon structure and regeneration of the gap area when compared with treatment using leukocyte-poor platelet-ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Soler, Robert, Rodas, Gil, Rius-Tarruella, Joan, Alomar, Xavier, Balius, Ramon, Ruíz-Cotorro, Ángel, Masci, Lorenzo, Maffulli, Nicola, Orozco, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498712/
https://www.ncbi.nlm.nih.gov/pubmed/37711505
http://dx.doi.org/10.1177/23259671231184400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498712/
https://www.ncbi.nlm.nih.gov/pubmed/37711505
http://dx.doi.org/10.1177/23259671231184400

Ejemplares similares